Axogen Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Axogen Inc trades at $49.25 (market cap $2.61B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $62 (market cap $78.85B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 30.2× Axogen Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.24% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | MDLZ | |
|---|---|---|
Market Cap | $2.61B | $78.85B |
Sector | Technology | Consumer Staples |
52-Week High | $48.48 | $64.99 |
52-Week Low | $14.16 | $51.51 |
Enterprise Value | $2.52B | $99.19B |
Dividend Yield | — | 3.24% |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $49.10, up 1.82% with strong technical momentum and bullish analyst sentiment. The stock shows robust revenue growth (23.1% in Q2 2026) and raised full-year guidance to $279 million, though profitability remains negative with a -13.36% net margin. Technical indicators show overbought RSI levels but strong moving average support, while institutional ownership and analyst consensus (84% buy ratings) signal confidence in the company's nerve care platform expansion.
The outlook remains positive given strong revenue momentum and regulatory advantages, but investors face execution risks from persistent losses and high valuation multiples. Upside potential exists toward the $54.33 consensus target if margin improvements materialize, though volatility may persist near current resistance levels.
Mondelez International (MDLZ) trades at $61.71, up 0.28% on the day, reflecting steady momentum after a series of earnings beats. The stock exhibits a bullish technical trend, supported by strong moving averages. Fundamentally, the company reported Q2 2026 EPS of $0.73, exceeding estimates, and raised its organic sales outlook for 2026. Revenue growth is solid, though net income margin compression from 2023 peaks remains a watch point. Analyst sentiment is overwhelmingly positive, with a consensus price target of $70.50 implying significant upside.
The outlook for MDLZ is favorable, driven by pricing power, volume growth in emerging markets, and a robust brand portfolio. Key opportunities include market share gains and consistent dividend payments. Primary risks involve exposure to international economic volatility, inflationary cost pressures, and intense competition in the snack food industry. The stock presents a compelling case for growth-oriented investors seeking stability in consumer staples.
Trailing returns across standard periods
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →